Alkermes Plc (ALKS)

18.50
NASDAQ
Prev Close 18.43
Day Low/High 18.33 / 18.57
52 Wk Low/High 11.98 / 21.86
Exchange NASDAQ
Shares Outstanding 159.15B
Market Cap 2.93B
P/E Ratio N/A
Div & Yield N.A. (N.A)
Two to Buy on the Dip

Two to Buy on the Dip

Talk of intensifying trade war is creating some bargains for investors.

Alkermes Downgraded to Hold at Jefferies

Alkermes Is Getting Ready for a Rally

Alkermes Is Getting Ready for a Rally

ALKS's choppy trading period may be coming to a close.

Alkermes Jumps on License Deal With Biogen -- Biotech Movers

Alkermes Jumps on License Deal With Biogen -- Biotech Movers

Alkermes and Biogen have inked a pact to develop and commercialize ALKS 8700, which is in Phase 3 development for treating relapsing forms of multiple sclerosis.

Making Sense of Thursday's Flood of Biotech and Pharma Earnings Reports

Making Sense of Thursday's Flood of Biotech and Pharma Earnings Reports

A guide to keep track of all the companies reporting first quarter financial results today -- making sense of what's important and disregarding what's not.

Could These 9 Drugs Gain FDA Approval in the Age of Trump?

Could These 9 Drugs Gain FDA Approval in the Age of Trump?

Nine biotech and drug companies want FDA approval, but need changed standards to get it.

The 'Gnarly 9' Biotechs Will Test the FDA's Mettle

The 'Gnarly 9' Biotechs Will Test the FDA's Mettle

The firms all have drugs they want the feds to bend the rules to approve.

Bullish and Bearish Reversals for the Week

Bullish and Bearish Reversals for the Week

Materials, financials, cyclicals and health care names tilt the scale to the bullish side.

Cramer: M&A Is Just the Beginning of Today's Story

Cramer: M&A Is Just the Beginning of Today's Story

Ask not for whom the register rings, and it better not ring for thee.

An Uninspiring Start

So much for the market opening flat. Futures took a tumble for the worse in the last hour before the open and equities are down across the board in early trading. The dollar is up nicely and oil is slightly down as we commence the last trading day o...

Alkermes upgraded at JP Morgan

Want a Dash for Trash? Why Not Look at Alkermes

Want a Dash for Trash? Why Not Look at Alkermes

Sometimes, buying low can work as a balance, almost a strange sort of diversification.

Stalking a Speculative Trade in Alkermes

Stalking a Speculative Trade in Alkermes

The longer-term weekly chart is ugly, but optimistic in the near-term.

Should Acadia, Alkermes Shares be at the Top of Your Buy List?

Should Acadia, Alkermes Shares be at the Top of Your Buy List?

Shares of Acadia Pharmaceuticals (ACAD) popped over 25% this week after an FDA panel voted in favor of approving its drug for Parkinson's disease psychosis.

Alkermes, Tesla & Disney Shares Set for Strong 2016 Performances

Alkermes, Tesla & Disney Shares Set for Strong 2016 Performances

Shares of Alkermes (ALKS) were up 30 percent in 2015 and the biotech company’s strong pipeline for psychiatric drugs bodes well for another strong year in the market.

Weak Chinese Demand Is Already Priced Into Caterpillar's Stock (Plus: MYL, T, DRG, URBN)

CAT not going down on bearish news gets us closer to a bottom and buy recommendation.

Charts of the Week: Boston Scientific, Alkermes, Snap-on, Stanley Black & Decker

Charts of the Week: Boston Scientific, Alkermes, Snap-on, Stanley Black & Decker

These four names stood out to me from a weekly perspective.

Alkermes upgraded at Morgan Stanley

Alkermes downgraded at Morgan Stanley

The Biotechs Are Feeling Better

The Biotechs Are Feeling Better

Sector could regain its leadership role.

A 'Who's Who' of Tax-Domicile Targets

A 'Who's Who' of Tax-Domicile Targets

Each of these 'real' American firms is now a buyout candidate because of the ridiculous U.S. tax code.

Alkermes upgraded at Mizuho

Alkermes price target raised at UBS

Alkermes downgraded at UBS

Alkermes rated new Outperform at Leerink

Alkermes downgraded at BofA/Merrill

Alkermes downgraded at Lazard